#USA #New York #Securities Law #Faruqi & Faruqi #Unicycive

Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is diligently investigating claims for investors who have suffered financial losses related to Unicycive Therapeutics, Inc. The firm has made a public appeal, urging those impacted to reach out directly to discuss their legal prospects.

The Background

Unicycive Therapeutics, listed under NASDAQ as UNCY, has been under scrutiny following significant allegations regarding its compliance with federal securities laws. The company's claims regarding its ability to meet FDA regulations have been called into question, particularly concerning their third-party manufacturing processes. As part of their updates, Unicycive issued a press release in June 2025, which unfortunately revealed that deficiencies had been identified in the Good Manufacturing Practice (cGMP) at a third-party vendor, consequently impacting its New Drug Application (NDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.

This press release was a catalyst for a dramatic decrease in Unicycive’s stock price, which plunged by nearly 41% following the news. Investors had anticipated a smoother approval process, which further complicated matters when the FDA issued a Complete Response Letter due to compliance failures. As a result, Unicycive's share price fell further, highlighting the gravity of the situation.

Legal Implications

With the deadline approaching for investors to seek the role of lead plaintiff in a federal class action, Faruqi & Faruqi is keen to ensure that affected stakeholders are well-informed about their options. The law firm underscores the importance of having a lead plaintiff who is representative of the class, capable of directing the legal proceedings effectively.

Investors are encouraged to make their voices heard, regardless of whether they wish to take the initiative in the litigation or simply to remain part of the potential recovery model. It's essential that stakeholders grasp the nuances of their rights within the context of this emerging legal landscape.

The Role of Faruqi & Faruqi, LLP

Since its establishment in 1995, Faruqi & Faruqi has been unwavering in its commitment to investor rights. With offices spanning New York, Pennsylvania, California, and Georgia, the firm has successfully recovered hundreds of millions of dollars for investors, setting a precedent for advocacy within securities law. Their extensive experience has positioned them as a leading voice in securities litigation, particularly concerning public companies like Unicycive.

The firm is not just focused on the current claims but is also gathering information from whistleblowers, former employees, and any potential witnesses that might shed light on Unicycive's operations and regulatory challenges. Investor input is vital in building a comprehensive case.

What Investors Should Do

For investors who acquired Unicycive securities between March 29, 2024, and June 27, 2025, now is the time to act. Engage with Faruqi & Faruqi to explore your options thoroughly. You may contact James (Josh) Wilson, a Senior Partner at the firm, directly at 877-247-4292 or through 212-983-9330 (Ext. 1310). Additional information can also be found on the firm’s dedicated webpage for this case: Faruqi & Faruqi – Unicycive Therapeutics.

The deadline for filing as a lead plaintiff is looming, and it represents a critical opportunity for affected investors to participate in the proceedings and possibly recover losses. Investors can choose to proceed independently or enlist legal assistance to navigate this complex environment.

Stay informed as this case evolves. For updates, follow Faruqi & Faruqi on social media platforms, including LinkedIn and X, and remain engaged with the ongoing conversation about investor rights and the implications of corporate responsibilities.